SS-31
Concentration calculator
Research summary
SS-31 (elamipretide) is a small mitochondria-targeted peptide designed to bind a lipid on the inner mitochondrial membrane, studied for its effect on stabilizing mitochondrial structure and energy-production efficiency in cells under metabolic stress.
In a published randomized trial in Barth syndrome, a genetic mitochondrial disorder, the initial randomized phase missed its primary endpoints. The open-label extension that followed showed statistically significant gains on a 6-minute walk test sustained through 168 weeks, plus measurable improvements on cardiac imaging. That long-term dataset, in a rare pediatric disease population, supported a 2025 FDA accelerated approval for Barth syndrome patients specifically —a disease-specific approval, not a general human-use finding.
Sources: Genetics in Medicine, 2021 (Thompson et al., PMC7935714); Genetics in Medicine, 2024 (168-week extension). Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.
Decoding the Benefits
- Walk-test performance improved significantly and held steady for more than three years of follow-up.
- Cardiac imaging showed measurable gains alongside the mobility improvements.
- That combined evidence was strong enough to earn FDA accelerated approval for a rare mitochondrial disease.
